N/A N=595 Implementation of Real-time ADE Surveillance and Decision Support
Adverse Drug Events
Primary: Time to Intervention Once an ADE Alert Has Fired in CPRS — 6.8; 8 hours to intervention — p=0.6680
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=60 Trial to Test if Antibiotic Ointments & Cream Will Sting After Application on a Minor Wound After Tape Stripping Injury
Sting
Primary: Mean Change From Post-Tape Stripping in Subject Assessment of Stinging Sensation Immediately After Investigational Product Application — -0.29; 0.82; -0.55; -0.65 units…
Phase 2 N=114 An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy
Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction
Primary: Immune-related Progression Free Survival (irPFS) as Per Assessment of a Blinded Independent Review Committee (IRC) According to Immune Related Response Criteria (irRC)…
Phase 3 N=145 A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
Diabetes · Diabetes Mellitus, Type 2
Primary: Change From Baseline (Visit 18) in Glycosylated Haemoglobin (HbA1c) at the End of Each 16 Week Treatment Period — -0.1; -0.1 percentage of glycosylated haemoglobin
Phase 3 N=237 Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
Glaucoma · Ocular Hypertension
Primary: Decrease From Baseline in Intraocular Pressure — 2.9; 1.6 mmHg
Phase 2 N=35 Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer
Cervical Adenocarcinoma · Cervical Adenosquamous Carcinoma · Cervical Squamous Cell Carcinoma
Primary: Overall Objective Response Rate (CR+PR) — 2; 5; 8 participants
N/A N=43 Association of Amino Acid Prevalence and Chronic Brain Injury
Chronic Traumatic Brain Injury
Primary: Change From Baseline of Concentrations of Essential Amino Acid at 1.5 Hours After Eating — 487.28; 553.70; 1224.19; 1339.54 µM
Phase 1 N=34 Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer
Prostate Adenocarcinoma
Primary: Partial Response in Bone Scan From Baseline to Week 6 — 9; 1; 6 participants
Phase 3 N=64 Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT)
HIV Infections · CMV Cytomegalovirus Retinitis
Primary: Survival — 6; 7; 3; 20 participants
N/A N=1,455 Prevention of Ischemic Events in Patients With Peripheral Arterial Disease
Peripheral Arterial Disease
Primary: Incidence of Major Cardiovascular Events — 112; 47; 51; 17 participants — p=<0.001
Phase 3 N=272 Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine
Diabetes · Diabetes Mellitus, Type 2
Primary: Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%) — -1.45; -1.33 Percent (%) glycosylated haemoglobin
Phase 3 N=209 Studies of the Ocular Complications of AIDS (SOCA)--Monoclonal Antibody CMV Retinitis Trial (MACRT)
HIV Infections · Cytomegalovirus Retinitis
Primary: Mortality Rate — 0.68; 0.31 deaths per person-year
Phase 3 N=362 A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus
Diabetes · Diabetes Mellitus, Type 1
Primary: Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%) — -0.3; -0.3 percentage (%)
Phase 3 N=193 Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
Glaucoma · Ocular Hypertension
Primary: Decrease From Baseline in Intraocular Pressure at Week 8 Predose — 3.5; 1.6 mmHg
Phase 3 N=24 A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes
Diabetes · Diabetes Mellitus, Type 1
Primary: Average Time Within Glycaemic Target Range (Above 70 mg/dL and Below 130 mg/dL) — 1.39; 1.09 hours